| 1.29 -0.008 (-0.62%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.58 |
1-year : | 1.68 |
| Resists | First : | 1.35 |
Second : | 1.44 |
| Pivot price | 1.34 |
|||
| Supports | First : | 1.21 |
Second : | 1.01 |
| MAs | MA(5) : | 1.31 |
MA(20) : | 1.34 |
| MA(100) : | 1.58 |
MA(250) : | 1.71 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.2  |
D(3) : | 24.2 |
| RSI | RSI(14): 38.8 |
|||
| 52-week | High : | 3.19 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RFL ] has closed below the lower bollinger band by 2.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ RFL ] is to continue within current trading range. It is unclear right now based on current values. 77.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.2 - 1.2 | 1.2 - 1.21 |
| Close: | 1.27 - 1.29 | 1.29 - 1.3 |
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Fri, 31 Oct 2025
Rafael Holdings Reports 2025 Financial Results and Strategic Progress - The Globe and Mail
Thu, 12 Jun 2025
Howard S. Jonas Acquires 13,080,457 Shares of Rafael Holdings, Inc. (NYSE:RFL) Stock - MarketBeat
Thu, 12 Jun 2025
Retail investors invested in Rafael Holdings, Inc. (NYSE:RFL) up 29% last week, insiders too were rewarded - simplywall.st
Thu, 12 Jun 2025
Rafael Holdings Up 29%, Insider Buyers Are Up 61% - Yahoo Finance
Wed, 11 Jun 2025
Rafael Holdings, Inc. SEC 10-Q Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 1.526e+007 (%) |
| Held by Institutions | 55.7 (%) |
| Shares Short | 154 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.617e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 633.4 % |
| Return on Equity (ttm) | -9.9 % |
| Qtrly Rev. Growth | 732000 % |
| Gross Profit (p.s.) | 9.05 |
| Sales Per Share | -31.51 |
| EBITDA (p.s.) | 644706 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.43 |
| Dividend | 0 |
| Forward Dividend | 57210 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|